German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

By K. Rahbar, H. Ahmadzadehfar, C. Kratochwil, U. Haberkorn, M. Schäfers, M. Essler, R. Baum, H. Kulkarni, M. Schmidt, A. Drzezga and 16 more. Journal of Nuclear Medicine, 2017

771 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/3a438302ee990aca2dc628d2357fc96af604a8eb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Fizazi
2. T. Beer
3. M. Morris
4. O. Sartor
5. K. Chi
6. J. D. de Bono
7. K. Rahbar
8. L. Nordquist

Citations in the corpus

• Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (2021, background): “22 (19) Did not receive 177Lu-PSMA-617 6 (5) Had adverse event 3 (3) Were withdrawn by investigator 3 (3) Had lack of clinical benefit 3 (2) Withdrew consent to treatment 2 (2) Died 2 (2) Had protocol deviation 2 (1) Had other reason 1 (1) Had progressive disease 18 (16) Did not receive standard car”